Clinical trials for Liver and bile duct cancer

133 currently recruiting clinical trials
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06923761 #2023-504845-30-00
Module 1 (Parties A, B, C, D) et module 2 (parties A et B) Tumeurs solides avancées
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Liver and bile duct cancer #NCT06923761 #2023-504845-30-00
Module 2 (Parties C et D) Cohorte 2 carcinome hépatocellulaire
Hepatocellular carcinoma Locally Advanced Metastatic Unhealthy A 1 2 Immunotherapy
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Lung cancer Colon cancer Rectal cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Cervical / Vulvar / Vaginal cancer #NCT07169734 #2025-521441-24-00
NSCLC (Non-Small Cell Lung Cancer) Cervical cancer Squamous NSCLC Adenocarcinoma Intrahepatic cholangiocarcinoma Urothelial carcinoma Squamous cell carcinoma Locally Advanced Metastatic 1 2
1 recruiting site
Alentis Therapeutics AG
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT05768139 #2023-000442-41
Cohortes autres tumeurs solides
Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses Squamous cell carcinoma HR Positive Locally Advanced Metastatic PIK3CA 1 2 3 or more
6 recruiting sites
Eli Lilly et compagnie
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT05118789
Locally Advanced Metastatic ROS-1 1
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Parties A1, A2, A3 (escalade de dose)
Locally Advanced Metastatic Metastatic Castration-resistant ATM 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B4
Locally Advanced Metastatic Metastatic Castration-resistant ATM 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B1
Locally Advanced Metastatic Metastatic Castration-resistant ATM 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Liver and bile duct cancer Head and neck cancer #NCT06725758 #2022-503061-29-00
NSCLC (Non-Small Cell Lung Cancer) Mesothelium Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses Hepatocellular carcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Squamous cell carcinoma Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Orion Pharma
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06833008 #2024-519184-18-00
Metastatic Other KRAS BRAF KRAS G12C KRAS non G12C NRAS HRAS KRAS G12D
Systemic Treatment-Naive
2 recruiting sites
Ipsen